Two new large studies of China's CoronaVac COVID-19 vaccine showed good efficacy against symptomatic infection and severe disease, albeit with lower efficacy than the two mRNA coronavirus vaccines currently in use.Overall 83.5% efficacy against infectionInterim efficacy and safety results from a phase 3 trial in Turkey were published yesterday in The Lancet.
A team led by researchers from Hacettepe University School of Medicine in Ankara randomly assigned either the inactivated whole-virion CoronaVac vaccine or a placebo to 10,214 healthcare and community volunteers aged 18 to 59 years at 24 centers from Sep 14, 2020, to Jan 5, 2021.